Looking at the various broker reports and referring to their NPV's, Arc is trading very close to below the NPV.No price at all factored in for exploration, appraisal etc etc.Prime take over target.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025